炎症性肠病治疗的新选择:肠道选择性整合素抑制剂维得利珠单抗  

A new treatment option of inflammatory bowel disease:gut selective integrin inhibitor-vedolizumab

作　　者：李慧博[1,2] 刘芳 翟所迪[1,2] LI Hui-bo;LIU Fang;ZHAI Suo-di(Department of Pharmacy,Peking University Third Hospital,Beijing 100191,China;Institute for Drug Evaluation,Peking University Health Science Center,Beijing 100191,China)

机构地区：[1]北京大学第三医院药剂科,北京100191 [2]北京大学医学部药物评价中心,北京100191

出　　处：《中国新药杂志》2021年第20期1841-1845,共5页Chinese Journal of New Drugs

基　　金：国家“重大新药创制”科技重大专项资助项目(2018ZX09201016):消化系统炎性疾病新药临床评价技术平台建设。

摘　　要：随着新型生物制剂作为治疗中/重度溃疡性结肠炎和克罗恩病更有效药物的出现,掌握其药理学作用机制、药动学参数以及临床疗效、安全性和经济性特征,对于炎症性肠病(inflammatory bowel disease,IBD)治疗的选择至关重要。维得利珠单抗(vedolizumab)作为一种新型肠道选择性单克隆抗体药物,可特异性结合α_(4)β_(7)整合素,阻止炎症细胞迁移到肠道,抑制肠道炎症反应,有较好的临床疗效和安全性。本文对新型生物制剂治疗IBD的作用机制、药动学、临床疗效、安全性和经济性进行综述,以期为临床应用提供参考。With the emergence of new biological agents as more effective drugs for the treatment of ulcerative colitis and Crohn’s disease,it is critical to understand their mechanisms,pharmacological characteristics and related clinical efficacy,safety and economic characteristics for the optimal treatment of inflammatory bowel disease(IBP).Vedolizumab is a new type of gut-selective monoclonal antibody that can specifically bind to α_(4)β_(7) integrin,prevent inflammatory cells from migrating to the intestine,inhibit intestinal inflammation,and has demonstrated satisfactory clinical efficacy and safety profiles.This article reviewed the mechanisms of action,pharmacokinetic/pharmacodynamic characteristics,clinical efficacy,safety and economy of vedolizumab,in order to provide guidance for clinical practice.

关 键 词：炎症性肠病 维得利珠单抗 作用机制 药动学/药效学 临床疗效 安全性 

分 类 号：R975[医药卫生—药品]